130 results about "Erythroid cell" patented technology

Provided herein is a recombinant protein comprising a transmembrane domain derived from a transmembrane domain of a wild type erythropoietin receptor (EPOR). Nucleic acid molecules encoding such recombinant proteins, recombinant constructs, vectors and cells containing the nucleic acid molecules, methods of producing such cells and therapeutic uses thereof are also provided.

The invention provides application of qi-blood foundation strengthening oral liquid in preparation of a medicine for building body and resisting aging, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by adopting the modes of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood not only has the effective component content, but also has the health-care effect. The oral liquid for consolidating qi and blood has the effects of improving the activity of superoxide dismutase of red blood cells and reducing the content of lipofuscin in tissues, can improve the exercise tolerance of rats, and has the effects of resisting aging and building the body.

The invention belongs to the technical field of biological medicine, and particularly relates to a chitosan modified gold nanocluster, a preparation method and application in red blood cell immobilization. According to the synthesis method of the CS-GSH-AuNCs cluster, a two-step low-temperature modification method is utilized, GSH-AuNCs core nanoparticles with a definite structure are synthesized firstly, then chitosan is modified through electrostatic interaction, the reaction condition is low temperature and nitrogen protection, the reaction condition is mild, the product repeatability is high, and the original structure of GSH-AuNCs is more complete. Experiments show that the CS-GSH-AuNCs cluster synthesized by the method has good acid and alkali tolerance and temperature tolerance, the effect of immobilizing red blood cells is good, and the biological safety is high.

A method for promoting erythrocyte differentiation is provided. A method for increasing RNA polymerase II arrest mediated by the MED26 polypeptide is also provided. Furthermore, a method for delivering reagents to cells is also provided.

The invention relates to an erythrocyte specific antibody screening test kit expressing a single antigen from a target erythrocyte (RBC) antigen (RhD and RhCE as 2 different antigens derived from RBC and 45 or more antigens in total including some variants of these two antigens) and a preparation method of this test kit. Said antigens are transgenically produced and provide the clearest results compared to traditional methods of antibody screening. Field-targeted mutation process is applied during the preparation of the erythrocyte-specific antibody screening test kit subject to the invention.

The present disclosure relates to methods of treating myelodysplastic syndrome. The present disclosure provides methods of treating myelodysplastic syndrome (MDS) in a subject not treated with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The methods comprise administering to the subject an effective amount of a telomerase inhibitor, such as, for example, imestat or imestat sodium. In some cases, a subject being treated is classified as a low or moderate-1IPSS risk MDS subject and / or has an erythropoiesis stimulating agent (ESA) recurrent / refractory MDS.

Reading device (10) for measuring the erythrocyte sedimentation rate starting from a blood sample consisting of a drop of a few microliters, which exploits capillarity to move the sample.

The invention belongs to the technical field of biology, and particularly relates to ANK1 gene nonsense mutation and application. The invention firstly provides an ANK1 gene non-sense mutation c.2230 Cgt and an ANK1 gene non-sense mutation c.2230 Cgt. The invention relates to the field of genetic engineering, and in particular relates to nonsense mutation T (p.Q744X), the nonsense mutation significantly reduces the expression of ankyrin, and further causes phenotypic changes such as abnormal cell morphology and increased osmotic fragility after K562 erythroid differentiation, which indicates that the K562 is related to the pathological process of hereditary polycythemia spheroides (HS), and indicates that the mutation has pathogenicity; secondly, a treatment evaluation system taking drug-induced translation readthrough and adenine base editing as a core is constructed around the mutation, a new strategy and a technical platform are provided for precise molecular treatment of the ANK1 nonsense mutant HS, and important clinical transformation prospects and application values are achieved.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

Compositions comprising Lumbricus terrestris erythrocruorin (LtEc) as an oxygen carrier for use in transfusion and organ perfusion are provided. In particular, methods of using acellular compositions comprising LtEc as a universal blood substitute for transfusion of patients are provided. The methods also include ex vivo perfusion of an organ or tissue with an oxygenated acellular perfusate comprising LtEc as an oxygen carrier. Additionally, methods are provided for using compositions comprising LtEc in treatment of acute ischemia and hyperbaric oxygen therapy.

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

The present disclosure relates to a SURF4 gene-knockout erythroid progenitor cell and a method of differentiating the same into an erythrocyte, wherein it has been determined that SURF4 gene-knockout cells, in which a SURF4 gene is knocked out in erythroid progenitor cells, express erythroid differentiation markers at a higher rate and undergo erythroid differentiation more rapidly under erythroid differentiation conditions according to the present disclosure, such that the present disclosure provides a method that enables rapid differentiation of erythrocytes using SURF4 gene-knockout erythroid progenitor cells.

The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and / or have MDS relapsed / refractory to Erythropoiesis-Stimulating Agent (ESA).

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

Provided herein are methods for detecting the presence of microfilariae in a blood sample. Generally, the methods include pouring a blood sample comprising erythrocytes onto a porous filter, wherein the porous filter captures microfilaria on a surface of the porous filter; drawing the erythrocytes through the porous filter, leaving a remaining sample on the surface of the porous filter; fluorescently labeling the remaining sample to form a labeled sample; washing the labeled sample; imaging the surface of the porous filter using an imaging system; and detecting the presence of microfilariae based on fluorescence in the images.

This invention discloses crystals of nitrogen-containing spiro compounds, methods for producing the same, and uses thereof. This invention provides a type I crystal of a nitrogen-containing spiro compound represented by formula A, in which the powder X-ray diffraction pattern displayed at a 2θ angle using Cu-Kα rays has diffraction peaks at positions 5.67±0.20°, 11.37±0.20°, 16.69±0.20°, 17.32±0.20°, and 19.73±0.20°. This invention also provides a type II crystal of a nitrogen-containing spiro compound represented by formula A, in which the powder X-ray diffraction pattern displayed at a 2θ angle using Cu-Kα rays has diffraction peaks at positions 11.32±0.20°, 11.70±0.20°, 11.93±0.20°, 18.03±0.20°, 18.81±0.20°, and 19.17±0.20°. The nitrogen-containing spiro compound crystals of the present invention exhibit good stability and complement factor D inhibitory activity, good inhibitory effect against rabbit erythrocyte hemolysis, high in vivo exposure levels, and high oral bioavailability. JPEG2026513298000037.jpg5469

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.

The utility model discloses an auxiliary sample liquid transfer device for erythrocyte sedimentation rate detection. Comprising a main machine body, a tube body inlet, a tube body operation cavity, a tube body carrying table, a loading table and a sample liquid transfer tube, wherein the tube body inlet and the tube body operation cavity are communicated with the main machine body; the tube body carrying table is arranged in the tube body operation cavity; the loading table is arranged below the front side of the main machine body and is used for placing a vacuum blood collection tube and a glass tube; the pumping driving unit acts on the sample liquid transfer pipe to generate directional negative pressure to realize sample liquid transfer, and the pipe body recycling unit is used for transferring and discarding the used sample liquid transfer pipe; by designing the flexible sample liquid transfer tube and integrating the pumping driving unit and the tube body recovery unit acting on the sample liquid transfer tube, accurate quantitative transfer of the sample liquid is realized, manual operation is replaced, the blood transfer working efficiency and quality are improved, and the sample liquid transfer tube is designed as a disposable consumable and can be automatically recovered after being used, so that the blood transfer efficiency is improved. And the use convenience and safety of the system are greatly improved.

The present invention relates to SURF4 gene-deficient erythroid progenitor cells and a method for differentiating same into erythroid cells. SURF4 gene-deficient cells in which the SURF4 gene has been knocked out of erythroid progenitor cells were found to express erythroid differentiation markers at a higher proportion and undergo erythroid differentiation more rapidly under erythroid differentiation conditions according to the present invention. Accordingly, the present invention provides a method for rapidly differentiating erythrocytes using SURF4 gene-deficient erythroid progenitor cells.

The present disclosure proposes a preparation method of a vesicle formed by an erythrocyte membrane encapsulating Newcastle disease virus, including: mixing a compacted erythrocyte solution, a phosphate buffered saline (PBS) solution, and Newcastle disease virus (NDV); centrifuging a resulting mixture of erythrocytes added with NDV; and resuspending and precipitating the centrifuged mixture with a PBS solution to obtain the vesicle formed by the erythrocyte membrane encapsulating Newcastle disease virus.

The present invention relates to ERRα gene-deficient erythrocyte progenitor cells and a method for differentiating erythrocytes thereof. It was confirmed that ERRα gene-deficient cells, in which ERRα genes are knocked out in erythrocyte progenitor cells, exhibit a higher expression level of erythrocyte differentiation markers and a more rapid progression of erythrocyte differentiation under erythrocyte differentiation conditions according to the present invention. Accordingly, the present invention provides a method for rapidly differentiating erythrocytes by using ERRα gene-deficient erythrocyte progenitor cells.

According to the invention, blood group antigens suitable for allogenic blood transfusion detection are screened and combined, and blood group antibody selection, fluorescent antibody screening, automatic cell cleaning program control, cleaning fluid selection, erythrocyte aggregation resistance, allogenic erythrocyte determination and other multi-condition combination methods are adopted. The detection rate of the positive sample of the allogenic blood transfusion stimulant is further effectively improved, and the accuracy of allogenic blood transfusion detection is improved.

This invention relates to the field of irregular antibody detection technology, specifically to an automated washing microfluidic chip for irregular antibody detection. The chip includes a chip body, a membrane, and a detection component comprising a sample application chamber and a detection chamber arranged sequentially away from the center of rotation. The sample application chamber and the detection chamber are connected by a washing channel. The detection component is pre-filled with a washing solution that can fill the detection chamber and the washing channel under centrifugation. The washing solution contains anti-human immunoglobulin that reacts with erythrocyte antigen-antibody complexes. The specific gravity of the washing solution is configured to be greater than the specific gravity of the sample to be tested but less than the specific gravity of the erythrocyte antigen. This configuration solves the problems of cumbersome procedures, excessive time consumption, high operator dependence, and difficulty in standardization caused by multiple manual washing steps required in traditional test tube methods for detecting irregular antibodies. It effectively ensures detection sensitivity and accuracy and reduces the false negative rate.

This invention belongs to the field of biomedical technology and provides a high-throughput drug screening system and its usage method for enriching circulating tumor cells (CTCs) in liver cancer. It includes an information processing and control unit; a diseased liver perfusion device comprising an organ chamber containing injection fluid at the bottom, an arterial supply line, an arterial end sensor, an arterial end clamp valve, at least two membrane lungs, a portal vein supply line, a portal vein end clamp valve, and a portal vein end sensor; a CTC enrichment device, which uses erythrocyte lysis to remove erythrocytes and immunomagnetic bead labeling to remove leukocytes, enabling the processing of large volumes of perfusion fluid in a single step to obtain enriched circulating tumor cells; a high-throughput drug screen; and phototubes, arterial end sensors, and portal vein end sensors, each electrically connected to the information processing and control unit. Compared with existing technologies, the high-throughput drug screening system and its usage method of this invention have the advantages of establishing a room-temperature mechanically perfused ex vivo liver cancer model, realizing the processing of large volumes of liquid specimens, and providing automated high-throughput drug screening functionality.

The present invention relates to UT2 gene-deficient erythroid progenitor cells and a method for differentiating same into erythrocytes. It was confirmed UT2 gene-deficient cells in which the UT2 gene is knocked out in erythroid progenitor cells exhibit a higher expression ratio of erythroid differentiation markers and more rapid progression of erythroid differentiation under erythroid differentiation conditions according to the present invention, Accordingly, the present invention provides a method capable of rapidly differentiating erythroid cells using UT2 gene-deficient erythroid progenitor cells.

The present application relates to the use of idasanutlin, or a pharmaceutically acceptable salt, a solvate, an isomer, or a functional derivative thereof for the treatment of hemoglobinopathies, including sickle cell disease, thalassemia, sickle cell beta thalassemia (Hb S / β Th), and leukocytosis as well as myeloproliferative conditions, polycythemia, and acute and chronic hemolytic anemia. It was found that idasanutlin increases HbF levels in multipotent erythroleukemia, hematopoietic stem cells, and sickle cell disease cells to provide another therapy for treatment of sickle cell disease.